

| | | |
|--|---------------------------|-------------------------------|
| APPLICANT (stamp or sticker acceptable) | PATIENT NHI: | REFERRER Reg No: |
| Reg No: | First Names: | First Names: |
| Name: | Surname: | Surname: |
| Address: | DOB: | Address: |
| | Address: | |
| | | |
| Fax Number: | | Fax Number: |

Risdiplam

Initial application — spinal muscular atrophy (SMA)

Applications from any relevant practitioner. Approvals valid for 12 months.

Prerequisites(tick boxes where appropriate)

| | |
|--------------------------|---|
| <input type="checkbox"/> | Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation |
| and | |
| <input type="checkbox"/> | Patient is 18 years of age or under |
| and | |
| <input type="checkbox"/> | Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age |
| or | |
| <input type="checkbox"/> | Patient is pre-symptomatic |
| and | |
| <input type="checkbox"/> | Patient has three or less copies of SMN2 |

Renewal — spinal muscular atrophy (SMA)

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 12 months.

Prerequisites(tick boxes where appropriate)

| | |
|--------------------------|---|
| <input type="checkbox"/> | There has been demonstrated maintenance of motor milestone function since treatment initiation |
| and | |
| <input type="checkbox"/> | Patient does not require invasive permanent ventilation (at least 16 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam |
| and | |
| <input type="checkbox"/> | Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy |

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz